Prostate International最新文献

{"title":"Second primary cancer risk and survival in prostate cancer patients: A nationwide analysis","authors":"Jihye Hyun ,&nbsp;Jooyoung Lee ,&nbsp;Tuan Thanh Nguyen ,&nbsp;Se Young Choi","doi":"10.1016/j.prnil.2025.01.004","DOIUrl":"10.1016/j.prnil.2025.01.004","url":null,"abstract":"<div><h3>Purpose</h3><div>Different treatments for prostate cancer (PC) could affect a patient’s risk of developing second primary cancers (SPCs). We assessed the incidence of SPC and overall survival (OS) after SPC diagnosis in patients with PC who underwent radical prostatectomy (RP) or radiation therapy (RT) as primary treatment.</div></div><div><h3>Methods</h3><div>Using the National Health Insurance Service database in South Korea, all male patients with PC between 2002 and 2018 were corrected for selection bias between the RT and RP groups by inverse probability of treatment weighting. The primary outcome was the incidence of SPC, and secondary outcome was OS after SPC diagnosis; cumulative incidence functions for competing risks of each SPC type were evaluated between the RP and RT groups. Cox regression analysis evaluated OS after SPC.</div></div><div><h3>Results</h3><div>Among 26,254 patients with PC, 20.3% and 79.7% were treated with RT and RP, respectively. Patients with PC had a 7% lower risk of all SPCs than the general male population [standardized incidence ratio (SIR) = 0.93]. Bladder (SIR = 1.65) and thyroid (SIR = 2.75) cancers were more common in both treatment groups. At 10-year follow-up, patients who underwent RP were less likely to have colon cancer than those who underwent RT [risk difference (%) = −0.9]. The former had a lower risk of death following lung (aHRs: 0.70; P = 0.010) and colon (aHRs: 0.53; P = 0.001) SPCs and a higher risk of death following esophageal SPC (aHRs: 6.9; P = 0.008).</div></div><div><h3>Conclusions</h3><div>SPC incidence and OS after SPC diagnosis may be influenced by the initial PC treatment. The choice of primary treatment for PC should guide the follow-up care and subsequent treatment strategies for SPCs.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 3","pages":"Pages 148-154"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of tamsulosin 0.4 mg for the treatment in male with the international Prostate Symptom Score ≥ 20 compared with tamsulosin 0.2 mg","authors":"Yu Seob Shin ,&nbsp;Jae Heon Kim ,&nbsp;Zhao Luo ,&nbsp;Lin Chuan ,&nbsp;Sung Chul Kam","doi":"10.1016/j.prnil.2025.03.002","DOIUrl":"10.1016/j.prnil.2025.03.002","url":null,"abstract":"<div><h3>Purpose</h3><div>Tamsulosin 0.2 mg is commonly used as the start dose for Asian benign prostatic hyperplasia (BPH) patients, while the 0.4 mg is recommended for Western countries. Recent studies reported that efficacy and safety of tamsulosin 0.4 mg is superior to that of tamsulosin 0.2 mg. However, there is a lack of evidence about the efficacy of tamsulosin 0.4 mg for a long time follow-up and focused on BPH patients who complained of severe International Prostate Symptom Scores (IPSSs). This study aimed to evaluate the efficacy of tamsulosin 0.4 mg compared with tamsulosin 0.2 mg in Korean BPH patients with severe IPSSs.</div></div><div><h3>Materials and methods</h3><div>We reviewed data from 13,115 men treated with tamsulosin for symptomatic lower urinary tract symptoms (LUTS) between January 2015 and June 2020. A total of 2,280 participants with a baseline total IPSS ≥20 who completed 4, 12, and 24-week follow-up IPSS and uroflowmetry (UFM) assessments without changing their initial tamsulosin dose were included. The participants were divided into two groups: Group 1 treated with tamsulosin 0.4 mg and Group 2 treated with tamsulosin 0.2 mg. The primary objective of the present study was to prove the superiority of tamsulosin 0.4 mg to 0.2 mg for improvement in total IPSS score and also prove it in IPSS subscores and UFM.</div></div><div><h3>Results</h3><div>Total IPSS for Group 1 (n = 984) had a significant decrease at four weeks compared with Group 2 (n = 1,296) (<em>P</em> = 0.027), and the obstructive subscore decreased more at 12 weeks in Group 1 than in Group 2 (<em>P</em> = 0.042). At four weeks, the maximum urinary flow rate (Qmax) significantly improved in Group 1 compared with Group 2 (<em>P</em> &lt; 0.011). However, there were no significant efficacy differences between the groups at 24 weeks.</div></div><div><h3>Conclusion</h3><div>This study demonstrates the potential superiority of tamsulosin 0.4 mg in improving IPSS and UFM parameters in Korean BPH patients with severe IPSS during the short-term follow-up. However, long-term efficacy requires further investigation.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 3","pages":"Pages 161-166"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of dyslipidemia in patients with prostate cancer","authors":"Tae Hyung Kim,&nbsp;Do Gyeong Lim,&nbsp;Ho Seok Chung,&nbsp;Eu Chang Hwang,&nbsp;Taek Won Kang,&nbsp;Dong Deuk Kwon,&nbsp;Seung Il Jung","doi":"10.1016/j.prnil.2025.03.005","DOIUrl":"10.1016/j.prnil.2025.03.005","url":null,"abstract":"<div><h3>Background</h3><div>The treatment of dyslipidemia in prostate cancer has been associated with a reduced risk of cancer progression and improved survival outcomes. The aim of this study was to examine the prevalence of dyslipidemia in patients newly diagnosed with prostate cancer and to identify the risk factors for newly detected dyslipidemia.</div></div><div><h3>Methods</h3><div>This retrospective study assessed the prevalence of dyslipidemia in patients who were newly diagnosed with prostate cancer and treated between 2010 and 2022. Patients who did not undergo anticancer treatments (surgery, radiation therapy, or medical androgen deprivation therapy) were excluded. The prevalence of dyslipidemia was analyzed according to disease status (localized vs. metastatic prostate cancer) and the duration of medical androgen deprivation therapy (ADT). Additionally, risk factors for newly detected dyslipidemia were evaluated.</div></div><div><h3>Results</h3><div>Out of 1,700 patients with prostate cancer (1,367 localized and 333 metastatic), 470 patients (27.6%) had dyslipidemia. The prevalence of previously existing dyslipidemia at the time of prostate cancer diagnosis (165 patients, 12.1%; 47 patients, 14.1%) and newly diagnosed dyslipidemia following treatment (199 patients, 14.6%; 59 patients, 17.7%) did not differ significantly between the localized and metastatic prostate cancer groups (<em>P</em> = 0.149; <em>P</em> = 0.311). The incidence of newly detected dyslipidemia increased significantly with the duration of ADT (&lt;1 year, 14.3%; 1–2 years, 16.0%; &gt;2 years, 24.7%; <em>P</em> = 0.001). Multivariable analysis revealed that ADT lasting more than 2 years was the only independent risk factor for newly detected dyslipidemia (OR, 2.80; 95% CI, 1.72–4.53; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The study demonstrated that a longer duration of androgen deprivation therapy was associated with a higher prevalence of dyslipidemia. Understanding the relationship between dyslipidemia and prostate cancer may help improve the management and treatment outcomes for patients with prostate cancer.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 3","pages":"Pages 174-178"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Hematospermia does not increase the risk of prostate cancer detection in prostate biopsy” [Prostate Int 12 (2024) 151–154]","authors":"Jae Ryun Park ,&nbsp;Sung Hyun Paick ,&nbsp;Woo Suk Choi ,&nbsp;Aram Kim ,&nbsp;Hyeong Gon Kim ,&nbsp;Benjamin I. Chung ,&nbsp;Hyoung Keun Park","doi":"10.1016/j.prnil.2025.06.003","DOIUrl":"10.1016/j.prnil.2025.06.003","url":null,"abstract":"","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 3","pages":"Page 179"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of transurethral resection of the prostate in benign prostatic hyperplasia patients with and without upper urinary tract dilatation: a propensity score matching analysis","authors":"Adem Utlu ,&nbsp;Tugay Aksakalli ,&nbsp;Isıl K. Aksakalli ,&nbsp;Ahmet E. Cinislioglu ,&nbsp;Ibrahim Karabulut","doi":"10.1016/j.prnil.2025.01.002","DOIUrl":"10.1016/j.prnil.2025.01.002","url":null,"abstract":"<div><h3>Background</h3><div>Upper urinary system dilation appears to be a precursor to the progression to renal failure as a result of benign prostatic hyperplasia (BPH). This study aimed to compare the outcomes of transurethral resection of the prostate (TUR-P) between BPH patients who develop upper urinary tract dilation (UUTD) and those in the normal group.</div></div><div><h3>Materials and methods</h3><div>Patients who underwent TUR-P for BPH diagnosis between 2019 and 2024 were included in the study. A propensity score matching was applied based on parameters such as age, International Prostate Symptom Score, prostate-specific antigen, prostate volume, serum creatinine, preoperative hemoglobin value, and presence of transurethral catheter. After the formation of the normal and UUTD patient groups, demographic and clinical data were compared. TUR-P outcomes, including International Prostate Symptom Score, clot retention, reoperation rates, blood transfusion rates, urinary retention rates, postoperative uroflow values, urodynamic requirements, and results were compared between the groups.</div></div><div><h3>Results</h3><div>After propensity score matching, a total of 128 patients who underwent TUR-P due to BPH, comprising 64 patients with UUTD and 64 patients with normal findings, were retrospectively reviewed. Mean hemoglobin level after TUR-P for UUTD group was 12.7 ± 1.9 g/dl, and for the normal group, it was 13.2 ± 2.1 g/dl. Postoperative clot retention rate UUTD and normal group was 4.7% and 3.1%, respectively. Blood transfusion rate for the UUTD group was 4.7%, and for the normal group, it was 1.6%. Postoperative urinary retention rate was higher in the UUTD group (18.7 vs. 9.4, <em>P</em> &lt; 0.05). Reoperation rate was 14% in the UUTD group and 7.8% in the normal group, with no statistically significant difference (<em>P</em> &gt; 0.05).</div></div><div><h3>Conclusions</h3><div>Although the rate of postoperative urinary retention is higher in patients with UUTD, which can lead to impaired kidney function during the course of BPH, TUR-P can be effectively performed without causing a significant increase in early or long-term complications.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 116-120"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The addition of peri-operative gentamicin with ciprofloxacin reduces infection and sepsis rates post transrectal prostate biopsy","authors":"Arjun Guduguntla ,&nbsp;Andrew Xu ,&nbsp;Kieran W. Benn ,&nbsp;Prassannah Satasivam","doi":"10.1016/j.prnil.2024.11.006","DOIUrl":"10.1016/j.prnil.2024.11.006","url":null,"abstract":"<div><h3>Objective</h3><div>Despite the advent of transperineal (TP) biopsy and reduced risk of infective complications, transrectal ultrasound-guided (TRUS) prostate biopsy is still widely performed worldwide. The accepted prophylactic antibiotic is usually a single agent oral fluoroquinolone; however, this approach is beset by growing antibiotic resistance. The aim of this study was to assess whether the addition of intravenous gentamicin (2 mg/kg or at least 160 mg), immediately prior to biopsy, in conjunction with routine ciprofloxacin prophylaxis, reduced infection and sepsis rates post TRUS biopsy.</div></div><div><h3>Method</h3><div>Six hundred fifty-eight patients underwent TRUS biopsy at our center from 2017 to 2022, of whom 648 had data sufficient for analysis. We performed a retrospective analysis focusing on patient demographics (age, BMI, diabetes status), biopsy parameters, and outcomes of sepsis and urinary tract infection . Patients were recorded as developing sepsis if they required hospital admission for intravenous antibiotics. Fisher's exact test was employed for categorical variables, while the Student's <em>t</em> test was utilized for continuous variables for statistical significance.</div></div><div><h3>Results</h3><div>The rate of sepsis was 3.9% in the ciprofloxacin-only group, versus 0% in the ciprofloxacin plus gentamicin group (<em>P</em> value = 0.03). Overall aggregated post-TRUS infection rates was also 0% in the ciprofloxacin plus gentamicin group (<em>P</em> value = 0.005). We found no associated between infection and secondary risk factors.</div></div><div><h3>Conclusion</h3><div>The administration of 2 mg/kg intravenous gentamicin with oral ciprofloxacin prophylaxis reduces infection and sepsis rates post TRUS biopsy.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 90-95"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the rarity: insights into primary diffuse large B-cell lymphoma of the prostate from a global retrospective analysis","authors":"Hejia Yuan ,&nbsp;Yongwei Li ,&nbsp;Jitao Wu ,&nbsp;Yining Zhao ,&nbsp;Fan Feng ,&nbsp;Hongwei Zhao ,&nbsp;Guohua Yu ,&nbsp;Peng Peng","doi":"10.1016/j.prnil.2024.11.008","DOIUrl":"10.1016/j.prnil.2024.11.008","url":null,"abstract":"<div><h3>Background</h3><div>The purpose of this study is to comprehensively analyze cases of primary diffuse large B-cell lymphoma of the prostate (P-DLBCL-P) from a global perspective, aiming to understand the disease's characteristics, treatment responses, and outcomes. By doing so, we seek to establish a valuable reference for the clinical management of this rare malignancy.</div></div><div><h3>Materials and methods</h3><div>This study conducted a retrospective review of P-DLBCL-P cases reported worldwide, using various online databases, including PubMed, Scopus, and other English databases, as well as WanFang Data and China National Knowledge Infrastructure in Chinese, collecting clinical pathology information, treatment modalities, and prognosis of patients, and conducted survival analysis using the Kaplan-Meier method.</div></div><div><h3>Results</h3><div>A cohort comprising 68 patients was enrolled in this study. Lower urinary tract symptoms were prevalent in 90.63% of cases. Furthermore, 89.5% of patients exhibited prostate-specific antigen levels below the threshold of 4 ng/mL. Prostate biopsy was the most commonly used method, accounting for 52.38% of cases, followed by transurethral resection of the prostate at 33.33%. Approximately 33.90% of patients diagnosed with prostate lymphoma experienced stage IV disease, with the bladder or ureter being the organs most frequently involved (53.33%). Surgical procedures were associated with an elevated risk of uncontrollable hemorrhage. Notably, chemotherapy demonstrated a positive therapeutic response, resulting in a complete remission rate of 50.94% and a partial remission rate of 28.30%. A subsequent follow-up study revealed a 1-year survival rate of 73.08% and a 3-year survival rate of 65.38%.</div></div><div><h3>Conclusions</h3><div>The symptoms of P-DLBCL-P are often atypical, leading to many patients being diagnosed at a later stage of the disease. Through a global study of cases, we have confirmed the efficacy of the rituximab–cyclophosphamide–adriamycin–vincristine–prednisone regimen as the preferred treatment option. Surgical intervention is typically only used for diagnostic purposes or to relieve organ obstruction.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 96-102"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia","authors":"Teak Jun Shin ,&nbsp;Ji Yong Ha ,&nbsp;Se Yun Kwon ,&nbsp;Dong Jin Park ,&nbsp;Jang Hwan Kim ,&nbsp;Sung Won Lee ,&nbsp;In Gab Jeong ,&nbsp;Ji Youl Lee ,&nbsp;Tag Keun Yoo ,&nbsp;Tae Hyoung Kim ,&nbsp;Du Geon Moon ,&nbsp;Sung Kyu Hong ,&nbsp;Jin Seon Cho ,&nbsp;Hong Sang Moon ,&nbsp;Jeong Woo Lee ,&nbsp;Seok Joong Yun ,&nbsp;Youn Soo Jeon ,&nbsp;Jong Gwan Park ,&nbsp;Taek Won Kang ,&nbsp;Ki Hak Moon ,&nbsp;Kyung Seop Lee","doi":"10.1016/j.prnil.2024.10.001","DOIUrl":"10.1016/j.prnil.2024.10.001","url":null,"abstract":"<div><h3>Objectives</h3><div>To determine and compare the efficacy and safety of GV1001 and 5 mg finasteride for benign prostatic hyperplasia (BPH) patients.</div></div><div><h3>Patients and methods</h3><div>This randomized, active-controlled, multicenter, phase 3 clinical trial enrolled 423 patients aged ≥50 years with a prostate volume (PV) &gt;30 mL. Patients were randomized into Group 1 (GV1001 0.56 mg + finasteride placebo), Group 2 (GV1001 1.12 mg + finasteride placebo), or Group 3 (GV1001 placebo +5 mg finasteride). The patients received the study drug during clinic visits every 2 weeks at weeks 0–22. Changes in the international prostate symptom score (IPSS), PV, maximum urinary flow rate (Qmax), prostate-specific antigen (PSA) level, residual urine volume, testosterone and dihydrotestosterone (DHT) levels, and international index of erectile function (IIEF) were assessed.</div></div><div><h3>Results</h3><div>We included 408 (96.45%) patients (Group 1, <em>n</em> = 138; Group 2, <em>n</em> = 134; Group 3, <em>n</em> = 136) in full analysis set for primary efficacy evaluations. All groups showed significant decreases and increases in the IPSS and Qmax, respectively (Groups 1, 2, and 3, IPSS: −4.78 ± 6.50, −4.99 ± 6.66, and −5.51 ± 6.42, respectively; <em>P</em> &lt; 0.0001; Qmax: <em>P</em> = 0.0005, <em>P</em> = 0.0039, and <em>P</em> &lt; 0.0001, respectively). PV reductions were observed in Groups 2 and 3 (−0.75 ± 8.21 mL [<em>P</em> = 0.3280] and −2.47 ± 7.92 mL [<em>P</em> = 0.0010], respectively). The PSA and testosterone levels of Group 3 significantly decreased and changed, respectively (−0.90 ± 1.25 ng/mL, <em>P</em> &lt; 0.0001 and <em>P</em> &lt; 0.0001, respectively). No significant differences were observed in the residual urine volume. DHT significantly decreased in all groups (Groups 1, 2, and 3: −71.41 ± 244.06 ng/mL [<em>P</em> = 0.0025], −73.84 ± 249.26 ng/mL [<em>P</em> = 0.0019], and −106.60 ± 178.29 ng/mL [<em>P</em> &lt; 0.0001], respectively). Only Group 3 exhibited a significantly decreased IIEF (−3.06 ± 15.34; <em>P</em> = 0.0323). Acute urinary retention occurred in one patient in Group 2. No patients underwent prostate surgery or minimally invasive procedures during the study.</div></div><div><h3>Conclusions</h3><div>GV1001 exhibited corresponding efficacy and tolerability, providing evidence of amelioration in urinary symptoms among patients with BPH in comparison to the use of 5 mg finasteride.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 81-89"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel","authors":"Satı Coşkun Yazgan ,&nbsp;Abdulkadir Sarı ,&nbsp;Hatice Bölek ,&nbsp;Emre Yekedüz ,&nbsp;Yüksel Ürün","doi":"10.1016/j.prnil.2024.11.007","DOIUrl":"10.1016/j.prnil.2024.11.007","url":null,"abstract":"<div><h3>Background</h3><div>To evaluate the prognostic value of the elimination rate constant K (KELIM), a marker of chemosensitivity, in mCRPC patients treated with docetaxel.</div></div><div><h3>Materials and methods</h3><div>The study included patients who had received first-line docetaxel for mCRPC. The KELIM score was calculated using PSA measurements obtained within the first 100 days of chemotherapy. The patients were divided into two groups based on the KELIM levels: KELIM PSA &lt;1 and KELIM PSA ≥1. The relationship between overall survival (OS) and the KELIM groups was evaluated.</div></div><div><h3>Results</h3><div>A total of 164 patients were included in this study. The median age was 68.1 years (interquartile range (IQR) 62.2-71.1). There were 76 and 88 patients in the KELIM PSA &lt;1 and KELIM PSA ≥1 groups, respectively. The median OS in the KELIM PSA ≥1 group (46.2 months, 95% confidence interval (CI): 38.8–53.6) was found to be longer than in the KELIM PSA &lt;1 group (32.0 months, 95% CI: 23.1–40.9) (<em>P</em> = 0.032). In multivariate analysis, the risk of death was independently higher in the KELIM PSA &lt;1 group than in the KELIM PSA ≥1 group (Hazard Ratio (HR): 1.58, 95% CI: 1.02-2.43, <em>P</em> = 0.037).</div></div><div><h3>Conclusions</h3><div>Higher KELIM scores are positively correlated with improved overall survival in mCRPC patients treated with docetaxel.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 103-106"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biopsy-free radical prostatectomy: a narrative review considering rationale, limitations, and current data","authors":"Arya Bahadori ,&nbsp;Jessie Woods ,&nbsp;Lance Yuan ,&nbsp;Louise Emmett ,&nbsp;John Yaxley ,&nbsp;Matthew J. Roberts","doi":"10.1016/j.prnil.2025.03.003","DOIUrl":"10.1016/j.prnil.2025.03.003","url":null,"abstract":"<div><div>Prostate biopsy prior to radical treatment for prostate cancer is a common practice worldwide to allow diagnosis, prognostication, and treatment planning. However, recent advances in prostate multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) have made the possibility of a “biopsy-free” radical prostatectomy, without prior biopsy, closer to reality than before. The biopsy-free approach serves to avoid investigation-related morbidity, health care resources, and time to definitive treatment, but is not without risk. Here we review the literature surrounding the rationale, limitations, and current data.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 67-73"},"PeriodicalIF":2.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}